Drug Research in China Falls Under a Cloud

Executives at the British drug maker GlaxoSmithKline were warned nearly two years ago about critical problems with the way the company conducted research at its drug development center in China, exposing it to potential financial risk and regulatory action, an internal audit found.

The confidential document from November 2011, obtained by The New York Times, suggests that Glaxo’s problems may go beyond the sales practices that are currently at the center of a bribery and corruption scandal in China. They may extend to its Shanghai research and development center, which develops neurology drugs for Glaxo.

Read Full Article HERE

Katie Thomas, The New York Times via CHINA US Focus http://feedproxy.google.com/~r/ChinaUsFocus/~3/upWuaOan0ro/